Journal
EXPERT REVIEW OF NEUROTHERAPEUTICS
Volume 15, Issue 1, Pages 83-105Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737175.2015.995637
Keywords
Alzheimer's disease; amyloid beta immunotherapy; bapineuzumab; biological markers; clinical trials; prevention; randomized controlled trials center dot systems biology; solanezumab; tau immunotherapy
Categories
Funding
- AXA Research Fund
- Fondation Universite Pierre et Marie Curie
- 'Fondation pour la Recherche sur Alzheimer', Paris, France
- program 'Investissements d'avenir' [ANR-10-IAIHU-06]
- Boehringer-Ingelheim
- Bristol-Myers Squibb
- Elan Corporation
- Novartis
- Eisai Inc.
- Pfizer Inc.
- Sanofi-Aventis
- Roche Pharmaceuticals and Diagnostics
- GE Healthcare
- Avid
- Eli Lilly and Company
- GlaxoSmithKline-Biologicals
- Jung-Diagnostics
- Cytox
- Takeda
- Isis Pharmaceutical Inc.
- NIH [P50 AG05142, NIA U01-AG10483, NIA U01-AG024904, NIA R01-AG030048, R01-AG16381]
- California Department of Health Services
- Academy of Finland
- Swedish Research Council
- Alzheimer Association
- EU
- Fonds de la recherche en sante du Quebec (FRSQ)
- Eli Lilly
Ask authors/readers for more resources
Worldwide multidisciplinary translational research has led to a growing knowledge of the genetics and molecular pathogenesis of Alzheimer's disease (AD) indicating that pathophysiological brain alterations occur decades before clinical signs and symptoms of cognitive decline can be diagnosed. Consequently, therapeutic concepts and targets have been increasingly focused on early-stage illness before the onset of dementia; and distinct classes of compounds are now being tested in clinical trials. At present, there is a growing consensus that therapeutic progress in AD delaying disease progression would significantly decrease the expanding global burden. The evolving hypothesis- and evidence-based generation of new diagnostic research criteria for early-stage AD has positively impacted the development of clinical trial designs and the characterization of earlier and more specific target populations for trials in prodromal as well as in pre- and asymptomatic at-risk stages of AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available